Vivos Therapeutics to acquire SOD Sciences stake and test interest
Vivos Therapeutics agreed to acquire a minority stake in SOD Sciences and a 50% interest in its proprietary pseudohypoxia test.
Story updates
12:53:45 PM UTC
SquawkNews
Vivos Therapeutics announced a strategic stock-for-assets transaction with SOD Sciences aimed at broadening its diagnostics platform and commercial channels. Vivos will issue $12 million of Series C Convertible Preferred Stock, convertible at $0.15 per share and subject to a 19.99% exchange cap pen…